1903-92-0

Basic information

• Product Name: 4,6-DICHLORO-2-METHOXYMETHYLPYRIMIDINE
• Synonyms: 4,6-DICHLORO-2-METHOXYMETHYLPYRIMIDINE;4,6-Dichloro-2-Methoxymethylpyrimidine(WX636054)
• CAS NO: 1903-92-0
• Molecular Formula: C₆H₆Cl₂N₂O
• Molecular Weight: 193
• Mol File: 1903-92-0.mol

Chemical Properties

• Melting Point: 71℃
• Boiling Point: 240℃
• Flash Point: 99℃
• Appearance: /
• Density: 1.389
• PKA: -4.90±0.30(Predicted)
• CAS DataBase Reference: 4,6-DICHLORO-2-METHOXYMETHYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-DICHLORO-2-METHOXYMETHYLPYRIMIDINE(1903-92-0)
• EPA Substance Registry System: 4,6-DICHLORO-2-METHOXYMETHYLPYRIMIDINE(1903-92-0)

Safety Data

• Hazardous Substances Data: 1903-92-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4,6-Dichloro-2-methoxymethylpyrimidine is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a key component in the development of new drugs.
Used in Agricultural Chemical Industry:
4,6-Dichloro-2-methoxymethylpyrimidine is also used as an intermediate in the synthesis of agricultural chemicals. Its properties make it suitable for the development of new pesticides and other agrochemicals.
Safety Precautions:
4,6-Dichloro-2-methoxymethylpyrimidine is considered to be a hazardous chemical and should be handled with care to avoid potential health hazards. It is typically stored and handled in a cool, dry, and well-ventilated area to ensure safety during its use in various applications.

Upstream product

• 1903-90-8 2-(methoxymethyl)pyrimidine-4,6-diol 

Downstream Products

• 1044641-84-0 2-bromomethyl-4-(3-chloro-phenyl)-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidine 
• 833463-32-4 4-(3-chloro-phenyl)-2-methoxymethyl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidine 
• 885068-92-8 (6-chloro-2-methoxymethyl-pyrimidin-4-yl)-[2-(2,4-dichloro-phenyl)-ethyl]-amine 

Relevant articles and documents

Compounds as syk kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

Substituted N-[pyrimidin-2-ylmethyl]carboxamides and their use as herbicides and plant growth regulators

What is described are N-[pyrimidin-2-ylmethyl]carboxamides of the formula (I) and their use as herbicides. In this formula (I), X1 and X2 are hydrogen or methyl, R1 to R4 are various radicals and A is an aromati

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES

Substituted heterocyclic diarylamine analogues of Formula I are provided: wherein X, Y and Z are independently N or optionally substituted C, and other variables are as described in the specification. Such compounds are ligands that may be used to modulat

BIARYL PIPERAZINYL-PYRIDINE ANALOGUES

Biaryl piperazinyl -pyri dine analogues are provided, of the Formula (I): wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands, for receptor localization studies.